Skip to main content

Study to Assess Adverse Events and Change in Disease Activity in Adult Participants With Advanced Solid Tumors Receiving Intravenous (IV) ABBV-400 as Monotherapy and in Combination With IV Bevacizumab

Active, not recruiting · Phase 1 · NCT05029882

Conditions: Non-Small Cell Lung Cancer, Advanced Solid Tumors, Gastroesophageal Adenocarcinoma, Colorectal Cancer

At a glance

Research payments reported, 2025
$3.9M
U.S. investigators named
27
Sites paid
22
Planned or actual enrollment
520

About the trial

Sponsor
AbbVie
Tested
ABBV-400 (drug), Trifluridine/Tipiracil (drug), Bevacizumab (drug)
Dates
Started 2021-10-13; completion 2027-11
Results posted
Not yet

Cancer is a condition where cells in a specific part of body grow and reproduce uncontrollably. The purpose of this study is to assess adverse events and change in disease activity when ABBV-400 is given to adult participants to treat advanced solid tumors. ABBV-400 is an investigational drug being developed for the treatment of advanced solid tumors. Study doctors put the participants in groups called treatment arms. The Recommended Phase 2 dose (RP2D) will be explored. Each treatment arm receives a different dose of ABBV-400. This study will include a dose escalation phase to determine the best dose of ABBV-400, followed by a dose expansion phase to confirm the dose and combination with…

From ClinicalTrials.gov, last updated 2025-10-29. Full record, eligibility and contacts (opens in a new tab)

Industry funding

AbbVie Inc. reported $3.9M in research payments for this study in 2025 (1,541 payments).

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

  • Pan American Center for Oncology Trials LLC $580,687
  • Yale University $485,549
  • Start Midwest LLC $485,252
  • Ut MD Anderson Cancer Center $424,787
  • Memorial Sloan Kettering Cancer Center $390,563
  • Next Virginia LLC $336,688
  • Duke University $285,091
  • Regents of the University of Colorado $178,951
  • Carolina Biooncology Institute PLLC $165,138
  • Exigent Research LLC $133,483
  • Community Hospital East, IN $90,221
  • Ronald Reagan UCLA Medical Center, CA $69,727
  • Sbq Radiology PLLC $68,570
  • Next Oncology $66,398
  • Comprehensive Cancer Centers of Nevada $60,329
  • Vx3 Imaging PC $16,400
  • $15,560
  • University of Illinois Hospital and Clinics, IL $13,450
  • Yale New Haven Hospital - Yale School of Medicine $600
  • Carolina Biooncology Institute $600
  • University of California San Diego Jacobs Medical Center $600
  • University of Colorado Denver School of Medicine $600
  • Duke Cancer Institute (dci) - Duke Cancer Center $600

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.